Patent 4294824 Issued on October 13, 1981. Estimated Expiration Date: October 13, 1998. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
424/534, Leucocyte424/533, Erythrocyte424/577, Hemic or immune system (e.g., hematopoietic system, bone marrow cells, etc.)530/351Lymphokines, e.g., interferons, interlukins, etc.
Extracts of the hemopoietic chalones, erythrocytic, lymphocytic and granulocytic chalones are produced by the semi-continuous processing of whole blood. By means of a continuous lysis unit the red blood cells are preferentially and substantially completely lysed while leaving unaffected the leucocytes which are then separated together with the red cell debris by means of a centrifuge in which the leucocytes attach to the rotor. The intact leucocytes are extracted and the extract subjected to ultrafiltration to provide extracts of the hemopoietic chalones, which may be further isolated and purified.Patients suffering from myeloid leukaemia have achieved temporary remissions with minimal serious or dangerous side effects when the patients received repeated doses of granulocytic chalone over an extended treatment period.
Other References
Rytomaa et al., Nature, vol. 222, Jun. 7, 1969, pp. 995-996
Rytomaa et al., Europ. J. Cancer, 1970, vol. 6, pp. 401-410
October 13, 1998. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
